Graves' disease Treatment Market Size (7MM) was ~USD 5 billion in 2025 and it is projected to grow at a significant CAGR by 2036

DelveInsight's "Graves' Disease Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Graves' Disease, historical and forecasted epidemiology as well as the Graves' Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore Graves' Disease Market Trends, treatment landscapes, and emerging therapies shaping the future @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Graves' Disease Market Report
• In January 2026, Viridian Therapeutics confirmed that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for veligrotug for the treatment of TED, formally assigning a highly anticipated PDUFA target action date of June 30, 2026.
• Among the 7MM, the US had the most prevalent cases of Graves' disease, compared to EU4, the UK, and Japan.
• In 2025, there were 7,198,000 cases of Graves' disease in the 7MM. The prevalence of Graves' disease in Japan is significantly lower than in Europe and the US.
• In 2025, the manifestation of Graves' disease in the US showed that Graves' Ophthalmopathy captured the highest number of cases, i.e., approximately 608,500 cases.
• Among the EU4 and the UK, the highest number of diagnosed prevalent cases of Graves' Disease in 2025 was found in Germany. While Spain accounted for the lowest number of diagnosed prevalent cases of Graves' Disease.
• The leading Graves' Disease Companies such as Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
• Promising Graves' Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Discover which therapies are expected to grab the Graves' Disease Market Share @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Graves' Disease Overview
Graves' disease is a disease affecting the thyroid and often the skin and eyes. Graves' disease is characterized by abnormal enlargement of the thyroid (goiter) and increased secretion of thyroid hormone (hyperthyroidism). Thyroid hormones are involved with many different systems of the body, and consequently, the specific symptoms and signs of Graves' disease can vary widely from one person to another.

Graves' Disease Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Graves' Disease
• Total Diagnosed Prevalent Cases of Graves' Disease
• Gender-specific Cases of Graves' Disease
• Graves' Disease Cases by Manifestations

Download the report to understand which factors are driving Graves' Disease epidemiology trends @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Marketed Graves' disease Drugs

• TEPEZZA (Teprotumumab-Trbw): Amgen (Horizon Therapeutics)
Teprotumumab, an insulin-like Growth Factor-1 receptor (IGF-1R) inhibitor, is a fully human IgG1 monoclonal antibody produced in Chinese hamster (CHO-DG44) cells with a molecular weight of approximately 148 KD. In January 2020, the US FDA approved TEPEZZA for the treatment of TED after an accelerated Priority Review. And recently, in September 2024, the drug was approved by Japan's Ministry of Health, Labour, and Welfare (MHLW) for the treatment of active Graves' orbitopathy. Additionally, in April 2024, Amgen announced its plans to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) in the near future. TEPEZZA is currently under investigation in Phase III clinical trials for patients with moderate-to-severe active Graves' orbitopathy as well as those with chronic TED characterized by a low Clinical Activity Score (CAS). Additionally, Amgen is exploring its potential for subcutaneous administration. To be continued in the report....

Emerging Graves' disease Drugs

• IMVT-1401 (batoclimab, RVT-1401): Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences
Immunovant's first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal FcRn. In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection. Currently, batoclimab is being developed as a low-volume SC injection for the treatment of a variety of IgG-mediated autoimmune disorders, including myasthenia gravis, TED, chronic inflammatory demyelinating polyneuropathy, and Graves' disease. The drug is currently in Phase III developmental stage.

• VRDN-001 (veligrotug): Viridian Therapeutics
Viridian's lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting Insulin-like Growth Factor-1 Receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves' ophthalmopathy. In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves' Ophthalmopathy therapy. The drug is being evaluated in various Phase III trials for the treatment of Graves' ophthalmopathy. According to a corporate presentation, its BLA was accepted in December 2025 and the potential PDUFA date of Veligrotug is June 30, 2026.

Get In-Depth Knowledge on Acute on Graves' disease Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Graves' Disease Companies
Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.

Graves' Disease Market Outlook
There are three main treatments for Graves' disease: ATD medications, thyroidectomy, and radioactive iodine therapy. ATD medications prevent the biosynthesis of the thyroid hormone by blocking iodide, the salted or reduced form of iodine, from interacting with thyroglobulin, thus diminishing the amount of hormone produced. Methimazole is the most widely used ATD medication, with a long half-life and low side effects. Another is carbimazole has been approved in European countries but is not approved in the United States. It is an inactive drug that is metabolized in the blood into the active methimazole thus it is less potent. And the last is propylthiouracil, which is the least potent of the available antithyroid medications. Approved in the United States and Europe, propylthiouracil is the initial treatment choice during the first trimester of pregnancy because of the low placental transfer. Propylthiouracil was, for many years, the first-choice ATD in both the USA and South America. But now the American Thyroid Association (ATA) recommends Methimazole over Propylthiouracil. Methimazole is used in most European countries and Japan, whereas carbimazole is mainly used in the UK.

Discover more about Graves' Disease Drugs in development @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Graves' Disease Market Report
• Coverage: 7MM
• Study Period: 2022-2036
• Graves' Disease Companies- Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
• Graves' Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
• Graves' Disease Therapeutic Assessment: Graves' Disease current marketed and Graves' Disease emerging therapies
• Graves' Disease Market Dynamics: Graves' Disease market drivers and Graves' Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graves' Disease Unmet Needs, KOL's views, Analyst's views, Graves' Disease Market Access and Reimbursement

Table of Contents
1. Graves' Disease Market Report Introduction
2. Executive Summary for Graves' Disease
3. SWOT analysis of Graves' Disease
4. Graves' Disease Patient Share (%) Overview at a Glance
5. Graves' Disease Market Overview at a Glance
6. Graves' Disease Background and Overview
7. Graves' Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graves' Disease
9. Graves' Disease Current Treatment and Medical Practices
10. Graves' Disease Unmet Needs
11. Graves' Disease Emerging Therapies
12. Graves' Disease Market Outlook
13. Country-Wise Graves' Disease Market Analysis (2020-2034)
14. Graves' Disease Market Access and Reimbursement of Therapies
15. Graves' Disease Market Drivers
16. Graves' Disease Market Barriers
17. Graves' Disease Appendix
18. Graves' Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.